These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9066328)

  • 21. Malignant hyperthermia--a large kindred linked to the RYR1 gene.
    Wallace AJ; Wooldridge W; Kingston HM; Harrison MJ; Ellis FR; Ford PM
    Anaesthesia; 1996 Jan; 51(1):16-23. PubMed ID: 8669559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia.
    Quane KA; Ording H; Keating KE; Manning BM; Heine R; Bendixen D; Berg K; Krivosic-Horber R; Lehmann-Horn F; Fagerlund T; McCarthy TV
    Br J Anaesth; 1997 Sep; 79(3):332-7. PubMed ID: 9389851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
    Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
    Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
    Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
    Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RYR mutation G1021A (Gly341Arg) is not frequent in Danish and Swedish families with malignant hyperthermia susceptibility.
    Fagerlund T; Ording H; Bendixen D; Islander G; Ranklev-Twetman E; Berg K
    Clin Genet; 1996 Apr; 49(4):186-8. PubMed ID: 8828983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia.
    Phillips MS; Khanna VK; De Leon S; Frodis W; Britt BA; MacLennan DH
    Hum Mol Genet; 1994 Dec; 3(12):2181-6. PubMed ID: 7881417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.
    Monnier N; Procaccio V; Stieglitz P; Lunardi J
    Am J Hum Genet; 1997 Jun; 60(6):1316-25. PubMed ID: 9199552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families.
    Iles DE; Lehmann-Horn F; Scherer SW; Tsui LC; Olde Weghuis D; Suijkerbuijk RF; Heytens L; Mikala G; Schwartz A; Ellis FR
    Hum Mol Genet; 1994 Jun; 3(6):969-75. PubMed ID: 7951247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.
    Moroni I; Gonano EF; Comi GP; Tegazzin V; Prelle A; Bordoni A; Bresolin N; Scarlato G
    J Neurol; 1995 Feb; 242(3):127-33. PubMed ID: 7751854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
    Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
    Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
    Sambuughin N; Sei Y; Gallagher KL; Wyre HW; Madsen D; Nelson TE; Fletcher JE; Rosenberg H; Muldoon SM
    Anesthesiology; 2001 Sep; 95(3):594-9. PubMed ID: 11575529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect.
    Sudbrak R; Golla A; Hogan K; Powers P; Gregg R; Du Chesne I; Lehmann-Horn F; Deufel T
    Hum Mol Genet; 1993 Jul; 2(7):857-62. PubMed ID: 8395939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cysteine-for-arginine substitution (R614C) in the human skeletal muscle calcium release channel cosegregates with malignant hyperthermia.
    Hogan K; Couch F; Powers PA; Gregg RG
    Anesth Analg; 1992 Sep; 75(3):441-8. PubMed ID: 1510267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel skeletal muscle ryanodine receptor mutation in a large Brazilian family with malignant hyperthermia.
    McWilliams S; Nelson T; Sudo RT; Zapata-Sudo G; Batti M; Sambuughin N
    Clin Genet; 2002 Jul; 62(1):80-3. PubMed ID: 12123492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia.
    O'Brien RO; Taske NL; Hansbro PM; Matthaei KI; Hogan SP; Denborough MA; Foster PS
    J Med Genet; 1995 Nov; 32(11):913-4. PubMed ID: 8592342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases.
    Broman M; Gehrig A; Islander G; Bodelsson M; Ranklev-Twetman E; Rüffert H; Müller CR
    Br J Anaesth; 2009 May; 102(5):642-9. PubMed ID: 19346234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.